Kalaris Therapeutics, Inc. (KLRS)
Market Closed
27 Jul, 20:00
NASDAQ (NMS) NASDAQ (CM) Primary NASDAQ (NMS) $
3. 58
-0.15
-4.0214%
$
87.9M Market Cap
- P/E Ratio
- Div Yield
71,654 Volume
-1.75 Eps
$ 3.73
Previous Close Want to track KLRS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Kalaris Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 13 | $75.01 | $54.53 | -$20.48 | -27.3% |
 David Kim Paradigm Biocapital Advisors LP | 700,000 | $5.91M | $2.94M | -$2.97M | -50.24% |
 Shawn M. McHugh WealthTrust Asset Management LLC | 20,416 | $106,840.32 | $76,151.68 | -$30,688.64 | -28.72% |
 Drew Phillips Fortitude Family Office LLC | 114 | $962 | $456 | -$506 | -52.6% |
 Belena Vincetti Fortis Capital Advisors LLC | 40,000 | $231,200 | $152,800 | -$78,400 | -33.91% |
 Jim Harding Propel Bio Management LLC | 295,771 | $1.83M | $1.08M | -$754,647.75 | -41.21% |
 Raymond Debbane Siren, L.L.C. | 435,798 | $3.47M | $1.63M | -$1.84M | -53.12% |
